Search Results - Mark Fereshteh

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1

    Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1 by Tyler Lahusen, Mark Fereshteh, Annabell S. Oh, Anton Wellstein, Anna T. Riegel

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for <i>Neu</i> (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice

    The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for <i>Neu</i> (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice by Mark Fereshteh, Maddalena T. Tilli, Sung Eun Kim, Jianming Xu, Bert W. O’Malley, Anton Wellstein, Priscilla A. Furth, Anna T. Riegel

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Targeted Disruption of β-Arrestin 2-Mediated Signaling Pathways by Aptamer Chimeras Leads to Inhibition of Leukemic Cell Growth

    Targeted Disruption of β-Arrestin 2-Mediated Signaling Pathways by Aptamer Chimeras Leads to Inhibition of Leukemic Cell Growth by Jonathan W. Kotula, Jin‐Peng Sun, Margie Li, Elizabeth D. Pratico, Mark Fereshteh, Douglas P. Ahrens, Bruce A. Sullenger, Jeffrey J. Kovacs

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    β-Arrestin2 mediates the initiation and progression of myeloid leukemia

    β-Arrestin2 mediates the initiation and progression of myeloid leukemia by Mark Fereshteh, Takahiro Ito, Jeffrey J. Kovacs, Chen Zhao, Hyog Young Kwon, Valerie A. Tornini, Takaaki Konuma, Minyong Chen, Robert J. Lefkowitz, Tannishtha Reya

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

    Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia by Chen Zhao, Alan Chen, Catriona Jamieson, Mark Fereshteh, Annelie Abrahamsson, Jordan Blum, Hyog Young Kwon, Juyong Brian Kim, John P. Chute, David A. Rizzieri, Michael J. Munchhof, Todd VanArsdale, Philip A. Beachy, Tannishtha Reya

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth

    Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth by James Kim, Jean Y. Tang, Ruoyu Gong, Juyong Brian Kim, John J. Lee, Karl V. Clemons, Curtis R. Chong, Kris S. Chang, Mark Fereshteh, Dale R. Gardner, Tannishtha Reya, Jun O. Liu, Ervin H. Epstein, David A. Stevens, Philip A. Beachy

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance

    Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance by Jinqi Liu, Joshua C. Curtin, Dan You, Stephen Hillerman, Bifang Li-Wang, Rukiye Eraslan, Jenny Xie, Jesse Swanson, Ching‐Ping Ho, Simone Oppenheimer, Bethanne M. Warrack, Colleen A. McNaney, David M. Nelson, Jordan Blum, Taeg Kim, Mark Fereshteh, Michael D. Reily, Petia Shipkova, Anwar Murtaza, Miguel A. F. Sanjuán, John T. Hunt, Luisa Salter–Cid

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity

    DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity by Alexander Muik, Homer Adams, Friederike Gieseke, Işıl Altıntaş, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Vanessa M Spires, Fulvia Vascotto, Aras Toker, Juliane Quinkhardt, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Tahamtan Ahmadi, Esther C.W. Breij, Özlem Türeci, Kate Sasser, Uğur Şahin, Maria Jure‐Kunkel

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

    Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors by Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke, Ravit Geva, Eytan Ben‐Ami, Corinne Maurice‐Dror, Emiliano Calvo, Patricia LoRusso, Guzmán Alonso, María E. Rodríguez-Ruiz, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Theodora W. Salcedo, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S. Plantinga, Aras Toker, Edward N. van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C.W. Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure‐Kunkel, Ignacio Melero

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: